Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06225414 · ClinicalTrials.gov registry record · NA

Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)

A NA study of Lung Cancer, sponsored by University of California, Irvine.

Active
Registry status
NA
Development phase
60
Enrollment target
10
Study locations

NCT06225414 is a NA study of Lung Cancer that is active but no longer recruiting, run by University of California, Irvine. The registered enrollment target is 60 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06225414, a NA study of Lung Cancer, is active but no longer recruiting, sponsored by University of California, Irvine.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
10
Study locations

Study Summary

The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of health insurance, perceived discrimination, language barriers, and limited health literacy. Lung cancer is the leading cause of cancer related mortality with 1.8 million annual deaths worldwide, with Hispanic patients known to have lower survival rates compared with non-Hispanic whites. Lung cancer screening (LCS) with low dose computed tomography (LDCT) decreases this mortality rate of lung cancer by 20%. Yet many Latinx patients who are eligible for lung cancer screening are still falling through the cracks which prevents patients the ability to detect lung cancer early. This study will test and compare the effect of a multi-level intervention on ordering LDCT within 4 months after patient enrollment to those in an Enhanced Usual Care. Our proposed intervention includes: * Primary care provider notifications of patients' LCS eligibility; * Patients' education; * Patients' referral to financial navigation resources; * Patients' reminder to discuss LCS during primary care provider (PCP) visit.

Conditions Studied

Lung Cancer

Interventions

  • OTHER Usual Care
  • BEHAVIORAL Patient education
  • BEHAVIORAL Brief Patient Education
  • BEHAVIORAL Referral to financial navigation resources
  • BEHAVIORAL Patient Reminders

Study Locations (10)

California

  • UCI Health Family Health Center - Anaheim - Anaheim
  • UCI Health-Costa Mesa - Costa Mesa
  • UCI Health-Irvine - Irvine
  • UCI Health-Laguna hilla - Laguna Hills
  • UCI Health-Newport - Newport Beach
  • UCI Health SeniorHealth Center -Pavillion 4 - Orange
  • UCI Medical Center, Pavilion 3 - Orange
  • UCI Health Family Health Center - Santa Ana - Santa Ana
  • UCI-Health Tustin - Tustin
  • UCI Health-Yorba Linda - Yorba Linda

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-02-12
Est. Completion 2026-02
Phase NA

Sponsor

University of California, Irvine

368 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06225414

The ClinicalTrials.gov registry entry for NCT06225414 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Usual Care is the first listed.

NCT06225414 reports 10 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06225414 about?

NCT06225414 is a clinical study titled "Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)". The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of he...

What is the current status of trial NCT06225414?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-02-12. Estimated completion is 2026-02.

What conditions does trial NCT06225414 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT06225414?

The interventions under investigation include: Usual Care (OTHER), Patient education (BEHAVIORAL), Brief Patient Education (BEHAVIORAL), Referral to financial navigation resources (BEHAVIORAL), Patient Reminders (BEHAVIORAL).

Who is sponsoring clinical trial NCT06225414?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06225414 being conducted?

This trial has 10 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.